A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (Q34628386)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

ChEBI release 2020-05-28

Parkinson's disease

1 reference

based on heuristic

inferred from title

Fabrizio Stocchi

object named as

Fabrizio Stocchi

9

0 references

object named as

Anthony Lang

5

0 references

8

object named as

Werner Poewe

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

10

object named as

Eduardo Tolosa

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1

object named as

Olivier Rascol

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Joseph Jankovic

4

object named as

Joseph Jankovic

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert A Hauser

3

object named as

Robert Hauser

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Charles Warren Olanow

13

object named as

C Warren Olanow

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

William John Langston

6

object named as

J William Langston

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

7

object named as

Eldad Melamed

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Cheryl J Fitzer-Attas

2

object named as

Cheryl J Fitzer-Attas

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Eli Eyal

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Yoni M Weiss

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

7 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

415-423

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

The scientific and clinical basis for the treatment of Parkinson disease (2009).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The therapeutic potential of monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Discordant effects of rasagiline doses in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Does rasagiline have a disease-modifying effect on Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Slowing the decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative responsiveness of Parkinson's disease scales to change over time.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

UPDRS activity of daily living score as a marker of Parkinson's disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Parkinson fatigue scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of fatigue on quality of life in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ageing and Parkinson's disease: substantia nigra regional selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms compensating for dopamine loss in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease progression, drug action and Parkinson's disease: why time cannot be ignored

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features at first visit and rapid disease progression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical heterogeneity in newly diagnosed Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression of motor impairment and disability in Parkinson disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Gender differences in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremor at onset. Predictor of cognitive and motor outcome in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of onset age on the clinical features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(11)70073-4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34628386&oldid=1756307014"